Fund Evaluator:
Rydex Biotechnology Inv (RYOIX)
Follow This Fund
Best Performing in Health Over the Last Year
| 77.3% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 77.1% | Fidelity Advisor Biotechnology I (FBTIX) |
| 71.4% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 71.0% | Fidelity Select Biotechnology (FBIOX) |
| 58.4% | Rydex Biotechnology Inv (RYOIX) |
Fund Details
Rydex Biotechnology Inv Overview
Rydex Biotechnology Inv (RYOIX) is an actively managed Sector Equity Health fund. Rydex Funds launched the fund in 1998.
The investment seeks to provide capital appreciation. Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.
About Rydex Biotechnology Inv (RYOIX)
There are 5 members of the management team with an average tenure of 8.84 years: Adrian Bachman (2022), Brendan Cain (2022), Spencer Crane (2022), Scott Miller (2022), Michael Byrum (1998). Management tenure is more important for actively managed funds than passive index funds.
The fund has 2 primary benchmarks: S&P 500 (TR) (1970) index with a weighting of 100% and S&P 500 Sec/Health Care TR USD index with a weighting of 100%. Rydex Biotechnology Inv has 76 securities in its portfolio. The top 10 holdings constitute 36.9% of the fund’s assets. The fund meets the SEC requirement of being classified as a nondiversified fund. The fund is not considered to have an ESG focus with its investment selection and management.
Rydex Biotechnology Inv is part of the Equity global asset class and is within the Sector Equity fund group. Rydex Biotechnology Inv has 5.3% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 94.7%. There is 5.3% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Rydex Biotechnology Inv has 0.2% of the portfolio in cash.
Assets Under Management
The fund has $114 million in total assets, which is below the $869 million average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
RYOIX Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Rydex Biotechnology Inv expense ratio is high compared to funds in the Health category. Rydex Biotechnology Inv has an expense ratio of 1.39%, which is 15% higher than its category average, making the fund expense ratio grade a D. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Rydex Biotechnology Inv has a portfolio turnover rate of 75%, indicating that holds its assets around 0.0 years. By way of comparison, the average portfolio turnover is 61% for the Health category.
Recently, in the month of June 2026, Rydex Biotechnology Inv returned 10.7%, which earned it a grade of B, as the Health category had an average return of 8.4%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all funds in that category.
Rydex Biotechnology Inv has a trailing yield of 0.00%, which is below the 0.39% category average. The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
Rydex Biotechnology Inv Grades
Year to date, the fund has returned 19.4%, 11.9 percentage points better than the category, which translates into a grade of A. The fund has returned 58.4% over the past year (grade of A), 18.8% over the past three years (grade of A) and 6.1% per year over the past five years (grade of B) and 10.4% per year over the past 10 years (grade of B).
For more mutual fund grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Rydex Biotechnology Inv, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
RYOIX Trailing NAV Total Returns Data as of 6/30/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| RYOIX Return (NAV) | 10.7% | 17.0% | 58.4% | 18.8% | 6.1% | 10.4% |
| RYOIX Grade | B | A | A | A | B | B |
| +/- Category | 2.2% | 5.1% | 24.8% | 7.9% | 0.9% | 0.4% |
| Health Avg | 8.4% | 11.9% | 33.6% | 11.0% | 5.2% | 10.0% |
| RYOIX Tax Cost Ratio | na | na | 2.7% | 2.0% | 2.4% | 2.0% |
RYOIX Annual NAV Total ReturnsData as of 6/30/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| RYOIX Return (NAV) | 19.4% | 30.7% | -0.7% | 6.1% | -13.1% | 1.8% | 22.1% | 25.0% | -9.0% | 29.7% | -19.5% |
| RYOIX Grade | A | A | F | B | D | F | C | D | F | A | F |
| +/- Category | 11.9% | 10.1% | -3.2% | 0.5% | -3.7% | -6.9% | -2.4% | -3.4% | -9.3% | 6.3% | -8.6% |
| Health Avg | 7.5% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 17.1% |
| Total Risk Index: | 1.41 - High |
| Category Risk Index: | 1.07 - High |
| Category Risk Grade: | F (85% Rank) |
| Beta: | 0.67 |
| R-Squared: | 24% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Mid-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.0% |
| Dividend Distribution: | Annually |
| Cap Gains Distribution: | Annually |
| Total Assets: | $136 Mil |
| Fund Total Assets: | $ 115 Mil |
| Share Class Type: | Inv |
| Portfolio Turnover: | 75% |
Management Team
| Number of Managers: 5 | |||
| Longest Tenure: 28.3 years | |||
| Average Tenure: 8.8 years | |||
| Managers (Year): Byrum Michael (1998), Bachman Adrian (2022), Cain Brendan (2022), Crane Spencer (2022), Miller Scott (2022) | |||
Portfolio Composition (as of 1/31/26)
| # of Holdings: | 76 |
| % in Top 10 Holdings: | 36.9% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 5.3% |
Portfolio Allocation |
|
| Domestic Stock: | 94.7% |
| Foreign Stock: | 5.3% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | -0.1% |
| Cash: | 0.2% |
Purchase Information
| Fund Family: | Rydex Funds |
| Phone Number: | 800-820-0888 |
| Website: | www.rydex-sgi.com |
| Status: | Open |
| Inception Date: | April 1, 1998 |
| Min. Initial Purchase: | $2,500 |
| Min. Initial IRA Purchase: | $1,000 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 1.39% ( Rating : High ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | Rydex Biotechnology Inv |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
